Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year

The company recognized $1.1M in grant revenue in the first quarter of 2025 compared to $1.7M in in the first quarter of 2024, which represents CPRIT’s share of the costs incurred for the REYOBIQ platform advancement for the treatment of patients with LM. “We improved our cash position in the first quarter as a result of both a financing and grant support,” said Marc Hedrick, M.D., Plus Therapeutics (PSTV) President and Chief Executive Officer. “With the additional cash and further anticipated grant support in 2025, we are well positioned to make solid progress in our 2 key business goals: enrollment in our REYOBIQ CNS cancer radiotherapeutic clinical trials and the planned launch of the CNSide cerebral spinal fluid assay platform.”